Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,187
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
CDZ173/Leniolisib, CDZ173/Leniolisib
Pharming Technologies B.V.
Activated Phosphoinositide 3-Kinase Delta Syndrome
1 trial -
CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib
Pharming Technologies B.V.
Activated Phosphoinositide 3-Kinase Delta Syndrome
1 trial -
An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease
Pharming Technologies B.V.
Adult patients with primary mitochondrial disease
1 trial -
CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib
Pharming Technologies B.V.
Common variable immunodeficiency
1 trial -
CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib
Pharming Technologies B.V.
primary immunodeficiency
1 trial -
An open-label cocktail drug-drug interaction (DDI) clinical study to assess the effect of multiple oral dosing with leniolisib on the pharmacokinetics (PK) of caffeine, midazolam, rosuvastatin, furosemide, and metformin in healthy subjects
Pharming Technologies B.V.
Activated Phosphoinositide 3-Kinase Delta Syndrome
1 trial -
An open-label, single-dose, parallel-group study to evaluate the plasma pharmacokinetics of leniolisib in subjects with impaired hepatic function and in subjects with normal hepatic function
Pharming Technologies B.V.
Activated Phosphoinositide 3-Kinase Delta Syndrome
1 trial -
CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib
Pharming Technologies B.V.
Activated Phosphoinositide 3-Kinase Delta Syndrome
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources